Research Disclaimer
This article reviews published scientific literature for educational purposes only. All compounds referenced are sold by Blank Peptides exclusively for in-vitro research and laboratory use. Nothing in this article constitutes medical advice, a treatment recommendation, or an endorsement of human use.
Melanotan II (MT-II) is a synthetic cyclic analog of alpha-melanocyte-stimulating hormone (α-MSH), developed at the University of Arizona in the early 1990s. It activates melanocortin receptors MC1R through MC5R — a non-selective binding profile that produces simultaneous effects across pigmentation, appetite, and other melanocortin-mediated pathways.
Receptor Pharmacology
MT-II binds with highest affinity to MC4R and MC1R in published binding assays. This multi-receptor profile means any research protocol must account for concurrent effects across multiple systems:
- MC1R activation — drives eumelanin synthesis in melanocytes (dark pigment responsible for UV-protective tanning)
- MC4R activation — modulates appetite and energy homeostasis in hypothalamic neurons
- MC3R/MC4R activation — implicated in sexual function pathways
Melanogenesis Research
The primary published research focus for MT-II is melanogenesis — specifically, stimulating eumelanin production through MC1R activation without UV exposure.
Key published findings:
- Dose-dependent increases in skin pigmentation in both animal models and human studies
- Increased eumelanin density provides measurable UV attenuation
- Research has explored whether peptide-induced melanogenesis can reduce UV-mediated DNA damage in skin models
Appetite and Metabolic Research
This has made MT-II a useful pharmacological tool for studying melanocortin-mediated appetite control, though its non-selectivity limits utility compared to MC4R-selective compounds being developed in the pharmaceutical pipeline.
Published Safety Observations
MT-II’s non-selective binding profile means a broad side effect range in published research:
- Nausea — particularly at initial exposures
- Facial flushing
- Appetite suppression
- Cardiovascular effects — linked to MC4R activation
- Unpredictable pigmentation distribution — including darkening of existing nevi, raising dermatological monitoring considerations
MT-II vs. Afamelanotide (Melanotan I)
- Afamelanotide — linear α-MSH analog with greater MC1R selectivity. More targeted melanogenesis with less off-target MC4R/MC3R activation. Has regulatory approval for erythropoietic protoporphyria, giving it a formal clinical safety dataset.
- Melanotan II — non-selective melanocortin agonist. For researchers studying broad melanocortin system pharmacology, MT-II’s non-selectivity is the point.
For researchers specifically studying melanogenesis, afamelanotide offers a cleaner tool. For researchers studying broad melanocortin system pharmacology, MT-II’s non-selectivity is the feature, not the limitation.
Browse These Compounds